LLY Intrinsic Value – ELI LILLY AND Reports Second Quarter FY2023 Earnings Results on August 8th

August 14, 2023

🌥️Earnings Overview

On August 8, 2023, ELI LILLY AND ($NYSE:LLY) reported their second quarter FY2023 earnings results ending June 30, 2023. Total revenue for the quarter was USD 8312.1 million, representing a 28.1% increase from the same period last year. Net income was USD 1763.2 million, an impressive 85.1% growth from the previous year.

Share Price

On the day of the announcement, ELI LILLY AND stock opened at $506.0 and closed at $521.6, representing a 14.9% surge in price from the prior closing price of $454.1. This increase in stock price can be attributed to the encouraging financial results reported by the company for the quarter. With such impressive financial results, ELI LILLY AND was able to surpass analysts’ expectations and demonstrate its economic strength. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for LLY. More…

    Total Revenues Net Income Net Margin
    29.52k 6.5k 24.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for LLY. More…

    Operations Investing Financing
    5.74k -2.55k -3.03k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for LLY. More…

    Total Assets Total Liabilities Book Value Per Share
    54.81k 43.66k 11.65
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for LLY are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    8.7% 8.3% 26.0%
    FCF Margin ROE ROA
    10.9% 43.1% 8.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – LLY Intrinsic Value

    At GoodWhale, we have conducted an extensive analysis on the fundamentals of ELI LILLY AND. According to our proprietary Valuation Line, the intrinsic value of ELI LILLY AND share is around $293.3. However, ELI LILLY AND stock is now traded at $521.6, which is overvalued by 77.8%. This means that investors may not be getting the best return on their investment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.

    – Biogen Inc ($NASDAQ:BIIB)

    Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.

    – Pfizer Inc ($NYSE:PFE)

    Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.

    – Merck & Co Inc ($NYSE:MRK)

    Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.

    Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.


    ELI LILLY AND reported strong financial results for the second quarter of FY2023, with total revenue reaching USD 8312.1 million and a net income of USD 1763.2 million, a notable year-on-year increase of 28.1% and 85.1%, respectively. This news was received positively in the stock market, as the stock price of the company moved up the same day. The impressive financial performance of ELI LILLY AND indicates a strong investment opportunity for potential investors, as it may be seen as an indication of long-term financial health and profitability.

    Recent Posts

    Leave a Comment